Early Data Show Antibody Cocktail Prevents Symptomatic COVID-19 Infection
REGEN-COV consists of 2 potent, virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein.
Article Type: MPR Drug News
Bamlanivimab Plus Etesevimab Cuts COVID-19 Hospitalization, Deaths
The combination therapy reduced the risk of hospitalization or death by 70%.
Shortage of Lead Poisoning Treatment Announced
Chemet is an orally active, heavy metal chelating agent indicated for the treatment of lead poisoning in pediatric patients.
Merck Ends Development of Two COVID-19 Vaccine Candidates
While both candidates were found to be generally well tolerated, findings showed immune responses that were inferior to those seen after natural infection or those reported with other COVID-19 vaccines.
FDA to Review Odevixibat for Progressive Familial Intrahepatic Cholestasis
Odevixibat is a potent, once-daily, non-systemic ileal bile acid transport inhibitor.
Zokinvy Now Available for Progeria, Processing-Deficient Progeroid Laminopathies
Zokinvy works by preventing farnesylation and subsequent accumulation of progerin and progerin-like proteins in the inner nuclear membrane.
Nerivio Device Cleared for Migraine in Adolescents
The approval was based on data from an open-label, single-arm study that evaluated the efficacy and safety of Nerivio in patients aged 12 to 17 years with migraine.
Moderna COVID-19 Vaccine Active Against Emerging Variants
In the US, a phase 1 study will evaluate mRNA-1273.351, an emerging variant booster candidate against the B.1.351 variant.
Lupkynis Approved for Active Lupus Nephritis
The approval was based on data from the pivotal phase 3 AURORA and phase 2 AURA-LV studies.
Study Reveals Previously Unknown Drug-Associated Arrhythmias
To identify medications with potential proarrhythmic association.
